DE19975031I2 - Verwendung von 4-Aminosalicyls{ure als entz}ndungshemmender Wirkstoff. - Google Patents

Verwendung von 4-Aminosalicyls{ure als entz}ndungshemmender Wirkstoff.

Info

Publication number
DE19975031I2
DE19975031I2 DE1999175031 DE19975031C DE19975031I2 DE 19975031 I2 DE19975031 I2 DE 19975031I2 DE 1999175031 DE1999175031 DE 1999175031 DE 19975031 C DE19975031 C DE 19975031C DE 19975031 I2 DE19975031 I2 DE 19975031I2
Authority
DE
Germany
Prior art keywords
inflammatory agent
acid
aminosalicyl
aminosalicyl acid
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE1999175031
Other languages
English (en)
Inventor
Myron Lover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stafford Miller Continental NV
Stafford Miller Ltd
Original Assignee
Stafford Miller Continental NV
Stafford Miller Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stafford Miller Continental NV, Stafford Miller Ltd filed Critical Stafford Miller Continental NV
Application granted granted Critical
Publication of DE19975031I2 publication Critical patent/DE19975031I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Glass Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE1999175031 1981-03-18 1982-03-18 Verwendung von 4-Aminosalicyls{ure als entz}ndungshemmender Wirkstoff. Active DE19975031I2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/245,035 US4440763A (en) 1981-03-18 1981-03-18 Use of 4-aminosalicyclic acid as an anti-inflammatory agent

Publications (1)

Publication Number Publication Date
DE19975031I2 true DE19975031I2 (de) 2004-09-23

Family

ID=22925050

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8282810125T Expired DE3277801D1 (en) 1981-03-18 1982-03-18 Use of 4-aminosalicylic acid as an anti-inflammatory agent
DE1999175031 Active DE19975031I2 (de) 1981-03-18 1982-03-18 Verwendung von 4-Aminosalicyls{ure als entz}ndungshemmender Wirkstoff.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE8282810125T Expired DE3277801D1 (en) 1981-03-18 1982-03-18 Use of 4-aminosalicylic acid as an anti-inflammatory agent

Country Status (7)

Country Link
US (1) US4440763A (de)
EP (1) EP0062000B1 (de)
AT (1) ATE31243T1 (de)
AU (1) AU554443B2 (de)
CA (1) CA1194419A (de)
DE (2) DE3277801D1 (de)
LU (1) LU90386I2 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
JPS57500432A (de) * 1980-03-20 1982-03-11
DE3151196A1 (de) * 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
USRE33239E (en) * 1983-09-06 1990-06-26 Farmaceutisk Laboratorium Ferring A/S Packaged stable enema solution or suspension containing 5-aminosalicyclic acid
US4657900A (en) * 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
AU1388388A (en) * 1987-04-01 1988-10-06 Dak-Laboratoriet A/S Benzoic acid derivatives and use thereof
US5484605A (en) * 1988-11-25 1996-01-16 Henning Berlin Gmbh Chemie-Und Pharmawerk Agent for treating chronically inflammatory intestinal diseases
DE3839839A1 (de) * 1988-11-25 1990-05-31 Henning Berlin Gmbh Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen
GB8909559D0 (en) * 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
US5378470A (en) * 1989-07-25 1995-01-03 Henning Berlin Gmbh Rectally administered pharmaceutical preparation
DE3924570A1 (de) * 1989-07-25 1991-01-31 Henning Berlin Gmbh Pharmazeutische zubereitung zur rektalen verabreichung
SE9000485D0 (sv) * 1990-02-09 1990-02-09 Pharmacia Ab Foamable composition for pharmaceutical use, use thereof and method of treatment
US5120306A (en) * 1990-03-21 1992-06-09 Gosselin Leon F Direct delivery of anti-inflammatories to the proximal small bowel
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US20030198640A1 (en) * 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US6551632B2 (en) 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
NZ500696A (en) * 1997-04-01 2002-05-31 Borody Thomas J Methods and compositions for treating inflammatory bowel disease comprising mycobacterial agents, including macrolides
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
EP1889198B1 (de) 2005-04-28 2014-11-26 Proteus Digital Health, Inc. Pharma-informatiksystem
US7498355B2 (en) 2005-05-27 2009-03-03 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
WO2006125293A1 (en) * 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP5421098B2 (ja) * 2006-06-06 2014-02-19 ジーアイケア ファーマ インク． トリメブチン及びｎ−脱メチル化トリメブチンの塩類
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
WO2008085484A2 (en) * 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
US7645801B2 (en) * 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
MX349677B (es) 2007-11-13 2017-08-08 Meritage Pharma Inc Composiciones corticosteroides.
DK3395372T3 (da) 2009-02-20 2022-04-19 Enhanx Biopharm Inc System til afgivelse af glutathion-baseret medikament
EP2427178B1 (de) 2009-05-06 2023-01-04 Laboratory Skin Care, Inc. Dermale freisetzungszusammensetzung mit wirkstoff-calciumphosphat-partikelkomplexen und anwendungsverfahren
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9765020B2 (en) 2012-05-23 2017-09-19 Cellix Bio Private Limited Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
CN104603100A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗炎症性肠病的组合物和方法
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
EP3212626B1 (de) 2014-10-27 2018-11-07 Cellix Bio Private Limited Drei-komponenten-salze des fumarsäuremonomethylesters mit piperazin und ethylendiamin zur behandlung von multipler sclerosis
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2639294A (en) * 1947-12-11 1953-05-19 Ferrosan Ab Method of producing nu-substituted derivatives of 4-amino-2-hydroxybenzoic acid
US2580195A (en) * 1948-01-31 1951-12-25 Ferrosan Ab Method of purifying 4-aminosalicylic acid
US2766278A (en) * 1951-08-10 1956-10-09 Rheinpreussen Ag 4-monoalkylaminosalicylic acids and 4-monoalkyloxyalkylaminosalicylic acids
US2711423A (en) * 1953-07-06 1955-06-21 American Cyanamid Co Neutral calcium 4-aminosalicylate hemihydrate and preparation of the same
US2874177A (en) * 1955-06-25 1959-02-17 Gohei Tanabe & Co Ltd Novel complex salt of 4-aminosalicylic acid and processes for producing the same
GB2021409B (en) * 1977-05-25 1982-09-22 Fisons Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
EP0062000A2 (de) 1982-10-06
US4440763A (en) 1984-04-03
AU554443B2 (en) 1986-08-21
DE3277801D1 (en) 1988-01-21
CA1194419A (en) 1985-10-01
EP0062000A3 (en) 1983-07-27
EP0062000B1 (de) 1987-12-09
AU8165982A (en) 1982-09-23
LU90386I2 (fr) 1999-06-24
ATE31243T1 (de) 1987-12-15

Similar Documents

Publication Publication Date Title
DE19975031I2 (de) Verwendung von 4-Aminosalicyls{ure als entz}ndungshemmender Wirkstoff.
DE3585981D1 (de) Behandlung gewebedegenerativer entzuendungskrankheiten.
DE3781177D1 (de) Gemischte phosphorsaeurediester, ihre herstellung und verwendung als entzuendungshemmende mittel.
IT1120991B (it) Procedimento per la preparazione del cloruro di cianurile allo stato solido
IT7925699A0 (it) Composizioni fotografiche di sbianca, e metodi per trattamento fotografico.
NL7902603A (nl) Overdracht en zuivering van halogeen en halogeenwater- stofzuur in een elektrochemisch systeem.
IT8223892A0 (it) Composizione di antralina migliorata e suo uso nel trattamento di malattie della pelle.
NL7900769A (nl) Monofilament van verbeterde op fluoride gebaseerde hars.
NO791425L (no) Nye dispersjoner.
ES8206465A1 (es) Un procedimiento para la preparacion de 4,5-diaril-&-cpolifluoralquil)-1-4-pirrol-2metanaminas antiinflamatorias.
DE3886371D1 (de) Herstellung des hblv-virus in der hsb-2 zell-linie.
NL7607137A (nl) Behandeling van afvalwater.
BR8203379A (pt) Composicoes herbicidas baseadas em derivados de cloro-aceto-ciclo-alquil-amidas
IT7922443A0 (it) Composizione oftalmica e metodo di impiego.
NO871494L (no) Funksjonalisering av iod-polyfluoralkaner ved elektrokjemisk reduksjon.
NL7904420A (nl) Chinolopyraan-4-on-2-carbonzuuresterderivaten en de toepassing daarvan als anti-allergische anti-astmatica.
IT7921144A0 (it) Sonda per la detreminazione elettrochimica del potenziale di ossigeno nellhatmosfera di un forno.
SU644924A1 (ru) Армоопалубочный пакет
FI824155L (fi) Foerfarande foer framstaellning av 3,7a-diazacyklohepta/j,k/fluoren
IT1120992B (it) Procedimento per la preparazione del cloruro di cianurile allo stato solido
IT7821837A0 (it) Struttura di mobile e suoi elementi per il rilassamento dell'organismo.
DE3482585D1 (de) Dihydroxybenzaldehydderivate als entzuendungshemmende mittel.
SU750981A1 (ru) 5-Сульфодиэтиламидо-2'-метокси-N-фенилантраниловая кислота, проявляющая противовоспалительную активность
SU873665A1 (ru) Этиловый эфир γ-фенил-γ-триэтилсилоксимасляной кислоты, обладающий противовоспалительной активностью
SU915438A1 (ru) Метиловый эфир 2-фенил-2-этилдибутилсилоксиуксусной кислоты, проявляющий противовоспалительную активность